Search

Glioblastoma multiforme (GBM) is the most common malignant tumour in the adult brain and hard to treat. Nuclear factor κB (NF‐κB) signalling has a crucial role in the tumorigenesis of GBM. EGFR signalling is an important driver of NF‐κB activation in GBM; however, the correlation between EGFR and the NF‐κB pathway remains unclear. In this study, we investigated the role of mucosa‐associated lymphoma antigen 1 (MALT1) in glioma progression and evaluated the anti‐tumour activity and effectiveness of MI‐2, a MALT1 inhibitor in a pre‐clinical GBM model. We identified a paracaspase MALT1 that is involved in EGFR‐induced NF‐kB activation in GBM. MALT1 deficiency or inhibition significantly affected the proliferation, survival, migration and invasion of GBM cells both in vitro and in vivo. Moreover, MALT1 inhibition caused G1 cell cycle arrest by regulating multiple cell cycle–associated proteins. Mechanistically, MALTI inhibition blocks the degradation of IκBα and prevents the nuclear accumulation of the NF‐κB p65 subunit in GBM cells. This study found that MALT1, a key signal transduction cascade, can mediate EGFR‐induced NF‐kB activation in GBM and may be potentially used as a novel therapeutic target for GBM.

Background Glioblastoma (GBM) is a fatal brain tumor, lacking effective treatment. Epidermal growth factor receptor (EGFR) is recognized as an attractive target for GBM treatment. However, GBMs have very poor responses to the first- and second-generation EGFR inhibitors. The third-generation EGFR-targeted drug, AZD9291, is a novel and irreversible inhibitor. It is noteworthy that AZD9291 shows excellent blood–brain barrier penetration and has potential for the treatment of brain tumors. Methods In this study, we evaluated the anti-tumor activity and effectiveness of AZD9291 in a preclinical GBM model. Results AZD9291 showed dose-responsive growth inhibitory activity against six GBM cell lines. Importantly, AZD9291 inhibited GBM cell proliferation > 10 times more efficiently than the first-generation EGFR inhibitors. AZD9291 induced GBM cell cycle arrest and significantly inhibited colony formation, migration, and invasion of GBM cells. In an orthotopic GBM model, AZD9291 treatment significantly inhibited tumor survival and prolonged animal survival. The underlying anti-GBM mechanism of AZD9291 was shown to be different from that of the first-generation EGFR inhibitors. In contrast to erlotinib, AZD9291 continuously and efficiently inhibited the EGFR/ERK signaling in GBM cells. Conclusion AZD9291 demonstrated an efficient preclinical activity in GBM in vitro and in vivo models. AZD9291 has been approved for the treatment of lung cancer with good safety and tolerability. Our results support the possibility of conducting clinical trials of anti-GBM therapy using AZD9291. Electronic supplementary material The online version of this article (10.1186/s13046-019-1235-7) contains supplementary material, which is available to authorized users.

The engineering of highly stable metal-organic frameworks (MOFs) will unveil the intrinsic potential of these materials for practical applications, especially for heterogeneous catalyzes. However, it is fairly challenging to rationally design robust MOFs serving as highly effective and reusable heterogeneous catalysts. Here, for the first time, we report the construction of four robust UiO-type chiral zirconium-metallosalen frameworks, denoted ZSF-1-4. Single-crystal X-ray-diffraction reveals that the frameworks consist of twelve-connected Zr6O8 clusters with privileged chiral metallosalen ligands anchored at ideal positions, generating confined chiral cages that enable synergistic activation. Unlike UiO-68 that is highly sensitive to aqueous solutions, ZSF-1-4 exhibit excellent chemical stability in aqueous solutions with a wide range of pH owing to the abundant hydrophobic groups within metallosalen ligands. These features render ZSF-1 and ZSF-2 to be excellent recycled heterogeneous catalysts for the conversion of imitated industrial CO2 with epoxides into cyclic carbonates with the highest reported turnover numbers in Zr-MOFs. With regard to asymmetric catalysis, ZSF-3 and ZSF-4 can effectively catalyze C-H azidation reaction in water medium with ee value up to 94%. Moreover, these robust ZSFs can be further extended to other analogues with various metal centers through demetallization-remetallization strategy, which renders them to be an excellent platform for broader fields.

Background Malignant glioma is the most common primary brain tumor in adults and has a poor prognosis. However, there are no effective targeted therapies for glioma patients. Thus, the development of novel targeted therapeutics for glioma is urgently needed. Methods In this study, we examined the prognostic significance BTK expression in patients with glioma. Furthermore, we investigated the mechanism and therapeutic potential of ibrutinib in the treatment of human glioma in vitro and in vivo. Results Our data demonstrate that high expression of BTK is a novel prognostic marker for poor survival in patients with glioma. BTK-specific inhibitor ibrutinib effectively inhibits the proliferation, migration and invasion ability of glioma cells. Furthermore, ibrutinib can induce G1 cell-cycle arrest by regulating multiple cell cycle-associated proteins. More importantly, we found that BTK inhibition significantly blocks the degradation of IκBα and prevents the nuclear accumulation of NF-κB p65 subunit induced by EGF in glioma cells. Conclusions Taken together, our study suggests that BTK is a novel prognostic marker and molecular therapeutic target for glioma. BTK is required for EGFR-induced NF-κB activation in glioma cells. These findings provide the basis for future clinical studies of ibrutinib for the treatment of glioma.

// Xuejiao Liu 1, 2, * , Ning Liu 1, 4, * , Chenglong Yue 1, * , Dacheng Wang 1 , Zhenglei Qi 1 , Yiming Tu 1 , Guokun Zhuang 1 , Di Zhou 1 , Shangfeng Gao 1, 2 , Mingshan Niu 3 and Rutong Yu 1, 2 1 Insititute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China 2 Brain Hospital, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China 3 Jiangsu Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, Jiangsu, China 4 Department of Neurosurgery, Huzhou Central Hospital, Huzhou, Zhejiang, China * These authors contributed equally to this work Correspondence to: Mingshan Niu, email: msniu24@126.com Rutong Yu, email: yu.rutong@163.com Keywords: glioma, FoxR2, proliferation, migration, p27 Received: August 31, 2016 Accepted: April 14, 2017 Published: April 27, 2017 ABSTRACT FoxR2 plays an important role in the development of many human tumors. However, the effects of FoxR2 on tumorigenicity of human glioma remain unclear. In this study, we investigated the roles of FoxR2 in cell proliferation and invasion of glioma. We found that overexpression of FoxR2 promoted the proliferation, migration and invasion of glioma cells. Knockout of FoxR2 induced G1 arrest by decreasing the expression levels of cyclin D1, cyclin E and p-Rb. Mechanistically, upregulation of FoxR2 increased the level and activity of MMP-2 and decreased the expression of p27. Furthermore, overexpression of FoxR2 decreased the nuclear accumulation of p27. Taken together, these results indicate that upregulation of FoxR2 may confer enhanced tumorigenicity in glioma cells.

Described here is a new and viable approach to achieve Pd catalysis for aerobic oxidation systems (AOSs) by circumventing problems associated with both the oxidation and the catalysis through an all-in-one strategy, employing a robust metal-organic framework (MOF). The rational assembly of a PdII catalyst, phenanthroline ligand, and CuII species (electron-transfer mediator) into a MOF facilitates the fast regeneration of the PdII active species, through an enhanced electron transfer from in situ generated Pd0 to CuII , and then CuI to O2 , trapped in the framework, thus leading to a 10 times higher turnover number than that of the homogeneous counterpart for Pd-catalyzed desulfitative oxidative coupling reactions. Moreover, the MOF catalyst can be reused five times without losing activity. This work provides the first exploration of using a MOF as a promising platform for the development of Pd catalysis for AOSs with high efficiency, low catalyst loading, and reusability.

Figure S1. AZD9291 pretreatment inhibited GBM cell migration. The cells were pretreated with AZD9291 for 24â h, and then the treated cells were used to conduct transwell migration assay (no Matrigel). Representative images of migratory abilities of AZD929-treated U251cells (A) and U87 cells (B). Figure S2. AZD9291 pretreatment inhibited GBM cell invasion. The cells were pretreated with AZD9291 for 24â h, and then the treated cells were used to conduct transwell invasion assays (Matrigel was added). Representative images of invasive abilities of AZD929-treated U251cells (A) and U87 cells (B). Figure S3. Combined with SCH772984, another ERK inhibitor significantly increases the sensitivity of GBM cells to AZD9291. (A and B) Measurement of cell proliferation after treating with AZD9291 or SCH772984 alone or their combinations by EdU incorporation assay. (C-F) U87 and U251 cells were incubated with AZD9291 or SCH772984 alone or their combinations for 30â h. Cell invasive abilities were evaluated by transwell invasion assay. (DOCX 3630 kb)

The engineering of highly stable metal-organic frameworks (MOFs) will unveil the intrinsic potential of these materials for practical applications, especially for heterogeneous catalyzes. However, it is fairly challenging to rationally design robust MOFs serving as highly effective and reusable heterogeneous catalysts. Here, for the first time, we report the construction of four robust UiO-type chiral zirconium-metallosalen frameworks, denoted ZSF-1-4. Single-crystal X-ray-diffraction reveals that the frameworks consist of twelve-connected Zr

Metal–organic frameworks (MOFs) imbedded privileged molecular catalysts are of particular interest due to their higher catalytic activities derived from the MOFs pore/channel confinement effect, improved lifetime through eliminating intermolecular deactivation pathway, and the recyclability based on their heterogeneity. In this work, a 3D chiral metallosalen-based MOF [Cd2(Cu(salen))(DMF)3]·DMF·3H2O (1) with a 1D open channel was synthesized and characterized by single-crystal X-ray diffraction and other physicochemical methods. Upon postsynthetic reduction modification with NaBH4, the conversion from imino to amino group on salen cores of 1 generates the reduction product 2 with a more flexible chiral group and more alkaline backbone, meanwhile still maintaining the original porous framework. 2 can be used as an efficient heterogeneous catalyst for the asymmetric Henry reaction with broad substrate applicability and exhibits higher activity and enantioselectivity (ee up to 98%) compared with the unreduce...

Malignant gliomas are associated with a high mortality rate. Thus, there is an urgent need for the development of novel targeted therapeutics. Aberrant Hedgehog signaling has been directly linked to glioma. GDC-0449 is a novel small molecule inhibitor of Hedgehog signaling that blocks the activity of smoothened (Smo). In this study, we evaluated the in vitro and in vivo effects of the smoothened inhibitor GDC-0449 on cell proliferation in human gliomas. We found that high expression of smoothened in glioma is a predictor of short overall survival and poor patient outcome. Our data suggest that GDC-0449 significantly inhibits the proliferation of glioma cells by inducing cell cycle arrest at the G1 phase. Our results demonstrate that GDC-0449 can effectively inhibit the migration and invasion of glioma cells. Furthermore, GDC-0449 treatment significantly suppressed glioma cell xenograft tumorigenesis. Mechanistically, GDC-0449 treatment markedly decreases the expression levels of key Hedgehog pathway component genes (Shh, Patched-1, Patched-2, smoothened, Gli1 and Gli2). These results indicate that GDC-0449 works through targeting the Hedgehog pathway. Taken together, our study suggests that smoothened could be used as a prognostic marker and molecular therapeutic target for glioma.

Background Malignant gliomas are associated with a high mortality rate, and effective treatment options are limited. Thus, the development of novel targeted treatments to battle this deadly disease is imperative. Methods In this study, we investigated the in vitro effects of the novel reversible chromosomal region maintenance 1 (CRM1) inhibitor S109 on cell proliferation in human gliomas. S109 was also evaluated in an intracranial glioblastoma xenograft model. Results We found that high expression of CRM1 in glioma is a predictor of short overall survival and poor patient outcome. Our data demonstrate that S109 significantly inhibits the proliferation of human glioma cells by inducing cell cycle arrest at the G1 phase. Notably, we observed that high-grade glioma cells are more sensitive to S109 treatment compared with low-grade glioma cells. In an intracranial mouse model, S109 significantly prolonged the survival of tumor-bearing animals without causing any obvious toxicity. Mechanistically, S109 treatment simultaneously perturbed the three core pathways (the RTK/AKT/Foxos signaling pathway and the p53 and Rb1 tumor-suppressor pathways) implicated in human glioma cells by promoting the nuclear retention of multiple tumor-suppressor proteins. Conclusions Taken together, our study highlights the potential role of CRM1 as an attractive molecular target for the treatment of human glioma and indicates that CRM1 inhibition by S109 might represent a novel treatment approach. Electronic supplementary material The online version of this article (doi:10.1186/s13045-016-0338-2) contains supplementary material, which is available to authorized users.

Knockdown of CRM1 inhibits the proliferation of glioma cells. (A) Expression of CRM1 was analyzed from 273 samples of different glioma types based on R2 genomics database. (B) U87 cells were infected with either a CRM1-specific shRNA or control shRNA. CRM1 knockdown was evaluated by immunoblotting. (C) The proliferation of U87 cells was measured by CCK-8 assay. Figure S2. S109 suppresses glioma cell proliferation in a time-independent manner. (A and B) U87 and U251 cells were treated with S109 at the indicated doses for different periods of time. Cell proliferation was assessed using the EdU incorporation assay. Figure S3. S109 reversibly inhibits the function of CRM1. (A and C) U87 and U251 cells were incubated with S109 or LMB for 2 h. Fixed cells were stained for RanBP1 and DAPI and analyzed by fluorescence microscopy. (B and D) U87 and U251 cells were treated with S109 or LMB for 2 h. Next, the inhibitors were washed out and fresh medium was added. The cells were further incubated for 2 h, stained with anti-RanBP1 and DAPI, and analyzed by fluorescence microscopy. Figure S4. The pharmacokinetic characteristics of S109 in plasma and cerebrospinal fluid (CSF). S109 (50 mg/Kg) was administered to rats via intraperitoneal injections. Blood and cerebrospinal fluid samples were collected at 10, 20, and 30 min post-dose. The concentrations of S109 in plasma and cerebrospinal fluid were determined by LC-MS/MS, respectively. (DOCX 5829 kb)